Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: The MITO 15 trial

Annals of Oncology

Volumn 27, Issue 3, 2016, Pages 487-493

  Lorusso, Domenica ^a   Scambia, G ^b   Pignata, S ^c   Sorio, R ^d   Amadio, G ^b   Lepori, S ^a   Mosconi, A ^e   Pisano, C ^c   Mangili, G ^f   Maltese, G ^a   Sabbatini, R ^g   Artioli, G ^h   Gamucci, T ⁱ   Di Napoli, M ^c   Capoluongo, E ^b   Ludovini, V ^e   Raspagliesi, F ^a   Ferrandina, G ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h Hospital of Mirano   (Italy)

ⁱ Hospital 'SS Trinità'   (Italy)

Author keywords

BRCA; Ovarian cancer; Trabectedin

Indexed keywords

CORTICOSTEROID DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; PLATINUM COMPLEX; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; PLATINUM DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER PATIENT; CANCER RECURRENCE; COMORBIDITY; CONTROLLED STUDY; DNA DETERMINATION; DNA EXTRACTION; DNA REPAIR; DNA SEQUENCE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SENSITIVITY; FEMALE; FOLLOW UP; GENE MUTATION; HEALTH STATUS; HUMAN; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NEXT GENERATION SEQUENCING; ONCOGEN BRCA; ONCOGENE; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT OVARIAN CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; VERY ELDERLY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; OVARIAN NEOPLASMS; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRCA1 PROTEIN; BRCA2 PROTEIN; DIOXOLES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; PROSPECTIVE STUDIES; TETRAHYDROISOQUINOLINES;

EID: 84959863353     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv608     Document Type: Article

References (26)

1. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474(7353): 609-615. doi: 10.1038/nature10166. Erratum in: Nature 2012; 490(7419): 298.
2. Product monograph [database on the Internet] 2010 (10 December 2014, date last accessed).
3. D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010; 9(8): 2157-2163.
4. Takebayashi Y, Pourquier P, Zimonjic DB et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001; 7(8): 961-966.
5. Erba E, Bergamaschi D, Bassano L et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001; 37(1): 97-105.
6. Soares DG, Machado MS, Rocca CJ et al. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells. Mol Cancer Ther 2011; 10(8): 1481-1489.
7. Tavecchio M, Simone M, Erba E et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 2008; 44(4): 609-618.
8. Delaloge S, Wolp-Diniz R, Byrski T et al. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. Ann Oncol 2014; 25(6): 1152-1158.
9. Alexandre J, Brown C, Coeffic D et al. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. Br J Cancer 2012; 106(4): 633-637.
10. Grosso F, Dileo P, Sanfilippo R et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 2006; 42(10): 1484-1490.
11. National Cancer Institute, Cancer Therapy Evaluation Program: Common Toxicity Criteria. Version 4.03, 2010. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14 (19 January 2016, date last accessed).
12. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228-247.
13. Concolino P, Costella A, Minucci A et al. A preliminary Quality Control (QC) for next generation sequencing (NGS) library evaluation turns out to be a very useful tool for a rapid detection of BRCA1/2 deleterious mutations. Clin Chim Acta 2014; 437: 72-77.
14. Karahalil B, Bohr VA, Wilson DM, III. Impact of DNA polymorphisms in key DNA base excision repair proteins on cancer risk. Hum Exp Toxicol 2012; 31(10): 981-1005.
15. Del Campo JM, Sessa C, Krasner CN et al. Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Med Oncol 2013; 30: 435.
16. Ferrandina G, Salutari V, Vincenzi B et al. Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study. Gynecol Oncol 2013; 130(3): 505-510.
17. Ang JE, Gourley C, Powell CB et al. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multiinstitutional study. Clin Cancer Res 2013; 19(19): 5485-5493.
18. O'Cearbhaill R, Zhou Q, Iasonos A et al. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecol Oncol 2010; 116: 326-331.
19. Monk BJ, Ghatage P, Parekh T et al. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Ann Oncol 2015; 26: 914-920.
20. Tan DS, Rothermundt C, Thomas K et al. 'Brcaness' syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with brca1 and brca2 mutations. J Clin Oncol 2008; 26(34): 5530-5536.
21. Lorusso D, Cirillo F, Mancini M et al. The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience. Oncology 2013; 85(2): 122-127.
22. Samuels BL, Chawla S, Patel S et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol 2013; 5: 258-272.
23. Lebedinsky C, Gomez J, Park YC et al. Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis. Cancer Chemother Pharmacol 2011; 68: 1223-1231.
24. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366(15): 1382-1392.
25. Edwards SL, Brough R, Lord CJ et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451: 1111-1115.
26. Norquist B, Wurz KA, Pennil CC et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011; 29: 3008-3015.